What is the 13F Pro Quality Score for ORGO?

13F Pro ranks Organogenesis Holdings Inc. (ORGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ORGO's current score at https://13fpro.ai/company/ORGO (free sign-up required for the full ranking).

Which hedge funds own the most ORGO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ORGO include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ORGO as soon as new 13F filings post.

Where does 13F Pro source ORGO data?

All Organogenesis Holdings Inc. fundamentals and ownership data come directly from SEC EDGAR. Organogenesis Holdings Inc. files with the SEC under CIK 1661181. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ORGO in?

Organogenesis Holdings Inc. (ORGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ORGO research updated on 13F Pro?

ORGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Organogenesis Holdings Inc.(ORGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661181 ORGO stock profile & AI dashboard →

13F Pro Quality Score

30.4/100

Rank #2,491 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

21.7/100

Profitability

14.9/100

Balance Sheet

11.2/100

Earnings Quality

54.2/100

Free Cash Flow

40.5/100

Institutional Flow

59.5/100

Revenue Scale

35.8/100

Dilution Risk

37.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ORGO Scores 30/100

exact factor attribution · 2026-09-11

ORGO's composite is held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.5 pts

60th pct

Earnings quality

+0.4 pts

54th pct

Shareholder dilution

-0.6 pts

37th pct

Free cash flow

-1.4 pts

41th pct

Earnings growth

-1.5 pts

20th pct

Scale

-2.1 pts

36th pct

Capital efficiency

-3.9 pts

11th pct

Profitability

-5.3 pts

15th pct

Revenue growth

-5.7 pts

22th pct

Latest change (2026-08-06): 21 → 44 · ↑ Profit margin 16→58; ↑ Free cash flow 18→50

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in ORGO

Events flagged as statistical outliers against ORGO's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
ORGO quality score jumped 23 points (20→44) on a new filing
View source filing →

ORGO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Organogenesis Holdings Inc. (ORGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORGO at 30.4/100 on a 32-signal composite quality model, placing it at rank #2,491 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (11.2) and profitability (14.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Organogenesis Holdings Inc. reports quarterly revenue of $43.8M, net income of $-96.3M, free cash flow of $-32.8M. Top institutional holders of ORGO by reported 13-F value include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock, based on the most recent SEC filings. ORGO trades on the Nasdaq exchange and files with the SEC under CIK 1661181. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organogenesis Holdings Inc. directly from SEC EDGAR. Organogenesis Holdings Inc.'s 13F Pro composite quality score has ranged between 29 and 66 since 2021, currently 30.4 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about Organogenesis Holdings Inc.

Quirks, history, and lore behind ORGO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Massachusetts · focused on regenerative medicine.
2
The Numbers
Annual revenue in the range of $200–250 million — small-cap territory — with a product portfolio spanning advanced wound care and surgical biologics.
3
The History
Founded in the 1980s, it was among the earliest companies to commercialize bioengineered human tissue, back when the idea sounded more like science fiction than surgery.
4
The Secret
Its products aren't drugs or devices in the traditional sense — they're living cell-based constructs and collagen matrices designed to help the body rebuild itself from the outside in.
5
The Lore
One of its flagship products, a bilayered cellular matrix, is essentially a lab-grown skin substitute used on diabetic foot ulcers and burns — real Frankenstein-but-make-it-helpful energy.
6
The Giveaway
The company's very name is a mashup of "organ" and "genesis" — because it literally grows human tissue replacements for a living, and its ticker is a tidy four-letter hint at that origin story.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$43.8M

Net Income

Q2 2026

$-96.3M

Free Cash Flow

Q2 2026

$-32.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+17.0% YoY

$564.2MFY 2025

FY22 $450.9MFY23 $433.1MFY24 $482.0MFY25 $564.2M

Net Income

+4201.0% YoY

$37.0MFY 2025

FY22 $15.5MFY23 $4.9MFY24 $861.0KFY25 $37.0M

Operating Income

+3583.6% YoY

$44.7MFY 2025

FY22 $22.3MFY23 $12.5MFY24 $-1.3MFY25 $44.7M

EPS (Diluted)

+1600.0% YoY

$0.15FY 2025

FY22 $0.12FY23 $0.04FY24 $-0.01FY25 $0.15

Total Assets

+20.3% YoY

$598.7MFY 2025

FY22 $449.4MFY23 $460.0MFY24 $497.9MFY25 $598.7M

Total Debt

—FY 2025

FY22 $71.3MFY23 $66.6MFY24 —FY25 —

Op. Cash Flow

-172.6% YoY

$-10.3MFY 2025

FY22 $24.9MFY23 $30.9MFY24 $14.2MFY25 $-10.3M

Free Cash Flow

-685.7% YoY

$-24.5MFY 2025

FY22 $-9.0MFY23 $6.6MFY24 $4.2MFY25 $-24.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$564.2M +17.0%	$482.0M +11.3%	$433.1M -3.9%	$450.9M -3.5%	$467.4M +38.2%	$338.3M
Net Income	$37.0M +4201.0%	$861.0K -82.6%	$4.9M -68.2%	$15.5M -83.5%	$94.2M +446.6%	$17.2M
Operating Income	$44.7M +3583.6%	$-1.3M -110.2%	$12.5M -43.8%	$22.3M -69.1%	$72.2M +170.5%	$26.7M
EPS (Diluted)	$0.15 +1600.0%	$-0.01 -125.0%	$0.04 -66.7%	$0.12 -82.9%	$0.70 +366.7%	$0.15
Total Assets	$598.7M +20.3%	$497.9M +8.2%	$460.0M +2.4%	$449.4M +1.4%	$443.3M +52.7%	$290.2M
Total Debt	—	—	$66.6M -6.6%	$71.3M -3.8%	$74.1M +5.8%	$70.0M
Operating Cash Flow	$-10.3M -172.6%	$14.2M -54.0%	$30.9M +24.4%	$24.9M -59.9%	$62.0M +1033.9%	$5.5M
Free Cash Flow	$-24.5M -685.7%	$4.2M -36.3%	$6.6M +172.5%	$-9.0M -129.4%	$30.8M +351.9%	$-12.2M

Get alerted when ORGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Organogenesis Holdings Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ORGO

MORGAN STANLEY
$28.5M11,721,609 sh
Soleus Capital Management, L.P.
$24.6M10,140,951 sh
BlackRock, Inc.
$17.6M7,249,528 sh
DIMENSIONAL FUND ADVISORS LP
$7.4M3,050,297 sh
AQR CAPITAL MANAGEMENT LLC
$7.3M3,011,753 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.1M2,905,919 sh
D. E. Shaw & Co., Inc.
$7.0M2,888,313 sh
Assenagon Asset Management S.A.
$4.8M1,967,952 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.7M1,935,554 sh
DEUTSCHE BANK AG\
$4.1M1,706,186 sh

Fund	Value	Shares
MORGAN STANLEY	$28.5M	11,721,609
Soleus Capital Management, L.P.	$24.6M	10,140,951
BlackRock, Inc.	$17.6M	7,249,528
DIMENSIONAL FUND ADVISORS LP	$7.4M	3,050,297
AQR CAPITAL MANAGEMENT LLC	$7.3M	3,011,753
VANGUARD CAPITAL MANAGEMENT LLC	$7.1M	2,905,919
D. E. Shaw & Co., Inc.	$7.0M	2,888,313
Assenagon Asset Management S.A.	$4.8M	1,967,952
GEODE CAPITAL MANAGEMENT, LLC	$4.7M	1,935,554
DEUTSCHE BANK AG\	$4.1M	1,706,186

Companies Similar to ORGO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

FOCL

EDAP TMS SA

AI score

Shared smart-money ownership · 3 shared holders

Soleus Capital Management, L.P.FLAX POND CAPITAL, LLC INTREPID FAMILY OFFICE LLC

INGN

Inogen Inc

AI score

Similar quality profile · 3 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC AIGEN INVESTMENT MANAGEMENT, LP Marquette Asset Management, LLC

USNA

USANA HEALTH SCIENCES INC

AI score

Similar quality profile · 2 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Verdad Advisers, LP

OFIX

Orthofix Medical Inc.

AI score

Similar quality profile · 2 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC HighMark Wealth Management LLC

PRLD

Prelude Therapeutics Inc

AI score

Similar quality profile · 2 shared holders

Soleus Capital Management, L.P.SPHERA FUNDS MANAGEMENT LTD.

EBS

Emergent BioSolutions Inc.

AI score

Similar quality profile

NVAX

NOVAVAX INC

AI score

Similar quality profile · 2 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Abel Hall, LLC

NOTV

Inotiv, Inc.

AI score

Similar quality profile · 2 shared holders

Hennion & Walsh Asset Management, Inc.NWAM LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ORGO on your watchlist

Track score changes the day Organogenesis Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ORGO a good stock to buy?

13F Pro's AI-powered analysis of Organogenesis Holdings Inc. (ORGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORGO are available on the ORGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ORGO is classified as a small company.

Which hedge funds own ORGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Organogenesis Holdings Inc.'s investment landscape.